IDEXX LABORATORIES INC /DE (IDXX)
In Vitro & In Vivo Diagnostic Substances
Latest Price
$559.07
TTM P/E
41.14
Normalized P/E
53.95
Div Yield
--
Book Value
19.54
P/B Ratio
28.62
Valuation metrics
adjust assumptions →EPS: $13.08
Book value / share: $20.14
Formula: √(22.5 × EPS × BVPS)
Graham Number
$76.99
86% downside
Norm. op. income: $932M (median of 7yr)
Tax rate: 20%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$90.16
84% downside
Base FCF: $773M (median of recent 5yr)
Growth: 21%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$547.31
2% downside
EPS: $13.08
Target P/E: 54×
Formula: EPS × P/E
P/E Fair Value
$706.32
+26% upside
Institutional Ownership
86.4% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.37M | $4.70B | 10.56% | -169.3K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.18M | $2.91B | 6.54% | -- | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.91M | $2.20B | 4.94% | -- | 2026-03-31 |
| STATE STREET CORP | 3.67M | $2.06B | 4.64% | +17.6K | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.66M | $1.50B | 3.36% | +77.1K | 2026-03-31 |
| Invesco Ltd. | 1.68M | $943.0M | 2.12% | +176.3K | 2026-03-31 |
| BAMCO INC /NY/ | 1.63M | $917.0M | 2.06% | -164.7K | 2026-03-31 |
| Bank of New York Mellon Corp | 1.50M | $845.0M | 1.90% | -119.9K | 2026-03-31 |
| Fundsmith LLP | 1.47M | $823.0M | 1.85% | -410.2K | 2026-03-31 |
| MORGAN STANLEY | 1.32M | $739.0M | 1.66% | -237.8K | 2026-03-31 |